-
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast CancerDaiichi Sankyo2022-12-09 10:53:06Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR
-
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03Daiichi Sankyo2022-12-08 13:03:04ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus
-
Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV eventsDaiichi Sankyo2022-12-08 10:41:45Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative
-
Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid lowering treatment algorithm might help more patients achieve LDL-C recommended goalsDaiichi Sankyo2022-09-06 16:43:43Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid
-
New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF)Daiichi Sankyo2022-09-06 16:40:26New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations
-
Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMODaiichi Sankyo2022-09-06 16:18:42Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
-
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2022-08-18 15:27:02ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice
-
ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based RegimensDaiichi Sankyo2022-08-18 15:16:38ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More
-
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenDaiichi Sankyo2022-08-18 15:09:25Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic
-
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative DiseaseDaiichi Sankyo2022-06-23 16:27:20Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic
